Clinical trial NCT02075957: Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer
Official title: Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Non-small Cell Lung Cancer
Keywords: Non-small cell lung cancer, adjuvant chemo-therapy, DNA chip
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2014-03-03
Enrollment: 192
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with non small cell lung cancer

Brief summary: Description of new transcriptional profiles associated with risk of relapse and identification of specific sites of relapse in non-small cell lung cancer, toxicity and resistance to adjuvant chemotherapy in completely resected non-small cell lung cancer (NSCLC).

Detailed description: * A first blood sample will be taken during the week before the operation. A second blood sample will be taken 4 to 8 weeks after the operation. And in case of relapse, a third sample will be taken. These samples are going to be stored in the collection of biological resources of Angers.
* Concerning the biopsy of the resected NSLCL, it will be sent to the collection of biological resources of Angers for conservation directly next to the surgery.

Eligibility criteria: Inclusion Criteria:

* Major subject
* Subject who received resection with primary non-small cell lung cancer at the University Hospital of Angers and whose tumor samples will be stored in collection of biological resources of University Hospital of Angers
* A written inform consent.

Exclusion Criteria:

* Under 18 year old;
* Pregnant or nursing women;
* Deprived of liberty;
* Age under curatorship or guardianship;
* Unable to consent person;
* About not carrying a non-small cell lung cancer.

Primary outcomes:
measure: Determination of news microarrays profiles of NSCLC relapse risks
timeFrame: 6 to 8 weeks after surgery
measure: Determination of news microarrays profiles of NSCLC relapse risks
timeFrame: At 1 year
measure: Determination of news microarrays profiles of NSCLC relapse risks
timeFrame: At 2 years
measure: Determination of news microarrays profiles of NSCLC relapse risks
timeFrame: At 3 years
measure: Determination of news microarrays profiles of NSCLC relapse risks
timeFrame: At 4 years
measure: Determination of news microarrays profiles of NSCLC relapse risks
timeFrame: At 5 years
measure: Determination of news microarrays profiles of NSCLC relapse risks
timeFrame: At 6 years
measure: Determination of news microarrays profiles of NSCLC relapse risks
timeFrame: At 7 years
measure: Determination of news microarrays profiles of NSCLC relapse risks
timeFrame: At 8 years
measure: Determination of news microarrays profiles of NSCLC relapse risks
timeFrame: At 9 years
measure: Determination of news microarrays profiles of NSCLC relapse risks
timeFrame: At 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Angers
country: France
facility: UH Angers
state: Maine et Loire
Study officials:
affiliation: University Hospital, Angers
name: José HUREAUX, Doctor
role: PRINCIPAL_INVESTIGATOR
References: